Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Oct 14;12(20):6527.
doi: 10.3390/jcm12206527.

Current Evidence for the Use of HIPEC and Cytoreductive Surgery in Gastric Cancer Metastatic to the Peritoneum

Anish J Jain  1 , Brian D Badgwell  1
Affiliations
Review

Current Evidence for the Use of HIPEC and Cytoreductive Surgery in Gastric Cancer Metastatic to the Peritoneum

Anish J Jain et al. J Clin Med. .

Abstract

Gastric cancer (GCa) is an aggressive malignancy, representing the third leading cause of cancer mortality worldwide. The poor prognosis of GCa can be associated with the prevalence of peritoneal metastasis (PM). Current international and national GCa treatment guidelines only recommend palliative treatment options for patients with PM. Since the 1980s there have been multiple single arm trials, randomized controlled trials, and metanalysis investigating the use of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced GCa, with or without PM. Results from these studies have been encouraging, with some large-volume centers even incorporating HIPEC into their treatment algorithms for patients with advanced GCa. Additionally, there are several ongoing trials that, when completed, will increase our understanding of the efficacy of CRS & HIPEC in patients with GCa metastatic to the peritoneum. Herein we review the current evidence, ongoing trials, consensus guidelines, and future considerations regarding the use of CRS & HIPEC in patients suffering from GCa with PM.

Keywords: HIPEC; cytoreductive surgery; gastric cancer; intraperitoneal chemotherapy; laparoscopic HIPEC; metastatic gastric cancer; peritoneal carcinomatosis; peritoneal metastasis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
MD Anderson’s integration of laparoscopic HIPEC into the treatment algorithm for patients with gastric adenocarcinoma metastatic to the peritoneum (courtesy of the University of Texas MD Anderson Cancer Center).
See this image and copyright information in PMC

References

    1. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021;71:209–249. doi: 10.3322/caac.21660. - DOI - PubMed
    1. Manzanedo I., Pereira F., Pérez-Viejo E., Serrano Á. Gastric Cancer with Peritoneal Metastases: Current Status and Prospects for Treatment. Cancers. 2023;15:1777. doi: 10.3390/cancers15061777. - DOI - PMC - PubMed
    1. Rau B., Feldbrügge L., Gronau F., Alberto Vilchez M.E., Thuss-Patience P., Bonnot P.E., Glehen O. Indication of Hyperthermic Intraperitoneal Chemotherapy in Gastric Cancer (Gastripec, Gastrichip) Visc. Med. 2022;38:81–89. doi: 10.1159/000522604. - DOI - PMC - PubMed
    1. Gamboa A.C., Winer J.H. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer. Cancers. 2019;11:1162. doi: 10.3390/cancers11111662. - DOI - PMC - PubMed
    1. Zhang J.F., Lv L., Zhao S., Zhou Q., Jiang C.G. Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Combined with Surgery: A 12-Year Meta-Analysis of this Promising Treatment Strategy for Advanced Gastric Cancer at Different Stages. Ann. Surg. Oncol. 2022;29:3170–3186. doi: 10.1245/s10434-021-11316-z. - DOI - PubMed

LinkOut - more resources